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Objectives The aim of this study was to analyze the risk factors and mid-term outcomes associated
with post-procedure heart blocks (PPHBs) after transcatheter closure of perimembranous ventricular
septal defect (pmVSD).
Background The development of heart blocks remains a major challenge for transcatheter closure
of pmVSD.
Methods Transcatheter closure of pmVSD was carried out in 228 patients. Electrocardiography and
24-h Holter monitoring were performed before the procedure, within 1 week after the procedure,
then 1, 3, 6, and 12 months, and every year thereafter.
Results Thirty-three patients (14.5%) who received transcatheter closure of pmVSD developed
PPHBs. PPHBs included right bundle branch block (57.6%), left bundle branch block (24.2%), and
atrioventricular block (18.2%). High-degree atrioventricular blocks occurred in 4 patients and recov-
ered to normal conduction after intravenous administration of hydrocortisone. PPHBs recovered to
normal conduction in 21 patients by the time of hospital discharge. Compared with the patients
without PPHBs, the patients suffering PPHBs were characterized by a signiﬁcantly longer distance
between the aortic valve and the defect (DAVD), a shorter distance from the lower rim of the defect
to the septal leaﬂet of the tricuspid valve (DLRD-SLTV), and a larger diameter difference between
the occluder and ventricular septal defect (DDOV). The earlier the PPHBs developed after the proce-
dure, the more difﬁcult the recovery to normal conduction.
Conclusions The outcome of PPHBs after transcatheter closure of pmVSD was satisfactory, as most
patients recovered to normal conduction. Measurements of DLRD-SLTV, DAVD, and DDOV may be
useful in predicting the incidence of PPHBs. (J Am Coll Cardiol Intv 2012;5:422–7) © 2012 by the
American College of Cardiology Foundation
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423Percutaneous device closure of perimembranous ventricular
septal defect (pmVSD) has shown great promise since the
year 2002 as a viable alternative to surgical closure (1–8).
However, a relatively high incidence of post-procedure
heart blocks (PPHBs) has also incurred attention, as they
affect the safety of the procedure and the prognosis of
patients (2,5,9–16). The exact incidence of PPHBs (mainly,
bundle branch block and atrioventricular block [AVB])
remains unclear. In addition, there is a lack of reports
describing risk factors and outcomes for PPHBs, which
would be especially useful for comparing transcatheter
approaches with other procedures, such as surgical repair.
An analysis of risk factors for PPHBs would also be useful
toward reducing the incidence of PPHBs.
The aim of this study was to determine the incidence, risk
factors, and outcomes for PPHB after transcatheter closure
of pmVSD.
Methods
Study population. Between January 2003 and December
2007, 244 patients underwent transcatheter closure of a
pmVSD. Besides the requirements for 8-kg body weight
and the presence of a left-to-right shunt, all inclusion
criteria depended on the results of transthoracic echocardi-
ography: 16-mm ventricular septal defect (VSD) diame-
ter, distance from the aortic valve to the upper rim of the
VSD 1 mm, a 9- to 11-o’clock position of the defect
across the short-axis parasternal view, and 70 mm Hg of
pulmonary pressure. Eventually, 228 patients (123 male,
105 female) successfully underwent transcatheter closure of
pmVSD. The median age was 14.1 years (range: 1.5 to 60
years), and the median weight was 38.9 kg (range: 11 to 89
kg). The procedure was unsuccessful in 16 patients due to
high atrioventricular block, aortic regurgitation, or a mod-
erate residual shunt. These 16 patients underwent surgical
closure eventually.
The local regulatory board of the First Affiliated
Hospital of Nanjing Medical University approved this
study. All the patients gave written informed consent
before the procedure.
Percutaneous device closure of pmVSD. The devices used in
his study were the Amplatzer asymmetrical ventricular
eptal occluder (AVSDO) (AGA Medical, Golden Valley,
innesota) and the symmetrical ventricular septal occluder
SVSDO) (Lifetech Scientific, Shenzhen, China) (2).
hese 2 devices are self-expandable double-disk devices
ade of nitinol wire mesh. The connecting waist (1.5-mm
ong) and right ventricle disk (4-mm larger than the waist)
f these 2 devices are the same. The only difference between
he 2 devices is the shape of the left disk. In the AVSDO, the
ortic end of the left ventricle disk is 0.5 mm larger than the
aist, and the other end is 5.5 mm larger than the waist,hereas in the SVSDO, the diameter of the left disk is
niformly 4 mm larger than the waist (2).
The implantation technique for these devices has been
escribed in detail previously (1,2). If the distance from the
ortic valve to the defect was 2 mm, AVSDO was
elected. Otherwise, AVSDO or SVSDO was randomly
sed. Briefly, the procedure was performed under general
nesthesia with transthoracic echocardiography and fluoro-
copic guidance. Standard right and left cardiac catheteriza-
ion and left ventricular angiography in long axial oblique
iew (60° left anterior oblique/20° cranial) were performed
o measure the pmVSD size and distance from the aortic
alve to the defect (DAVD)
Figs. 1 and 2) in all patients.
he size of either selected device
as 1 mm larger than the
easured pmVSD size. After
stablishment of the femoral ar-
erial and venous access port,
eparin (100 IU/kg) was infused
ntravenously. The selected de-
ice was gradually released out of
he sheath when it was delivered
o the site of the pmVSD. All
atients underwent left ventric-
lar angiography before and af-
er delivery of the device to en-
ure closure of the defect. If
here were no complications, pa-
ients were discharged 7 days
fter the procedure and kept on
ral aspirin (5 mg/kg daily) for 6
onths.
Measurements. All patients un-
erwent electrocardiography,
4-h Holter monitoring, and
ransthoracic echocardiography
efore and after the procedure.
ollow-up examinations were
erformed on an outpatient basis
nd scheduled at 1, 3, 6, and 12
onths and yearly thereafter. None
f the patients admitted to the hospital post-procedure were on
ontinuous telemetry (including ambulatory telemetry).
Electrocardiography and 24-h Holter monitoring. Electro-
cardiography was performed in all patients before and every
day after the procedure during their hospitalization. All
patients also underwent 24-h Holter monitoring before and
on the fifth day after the procedure. In addition, if patients
developed PPHBs, a 24-h Holter test was carried out again
on the fifth day after its development.
The criteria for a diagnosis of a PPHB (i.e., AVB or
bundle branch block) were: 1) the heart block developed
Abbreviations
and Acronyms
AVB  atrioventricular block
AVSDO  asymmetrical
ventricular septal occluder
CI  confidence interval
DAVD  distance from the
aortic valve to the defect
DDOV  diameter difference
between the occluder and
ventricular septal defect
DLRD-SLTV  distance from
lower rim of the defects to
the septal leaflet of the
tricuspid valve
LBBB  left bundle branch
block
OR  odds ratio
pmVSD  perimembranous
ventricular septal defect
PPHB  post-procedure
heart block
RBBB  right bundle branch
block
SOD  size of device
SVSDO  symmetrical
ventricular septal occluder
VSD  ventricular septal
defectexclusively after placement of the selected device, whereas
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424there had been no heart block before the procedure; or 2) if
there did exist a heart block before the procedure, newly
developed heart blocks after the procedure were different.
Figure 1. Distance From the Aortic Valve to the Defect
The blue bars show that the distance from the aortic valve to the defect
(DAVD) was 6.6 mm, as measured by left ventricular angiography.
Figure 2. The Perimembranous Ventricular Septal Defect Size
The blue bars show that the pmVSD size was 5.08 mm, as measured by left
ventricular angiography. pmVSD  perimembranous ventricular septal defect.Transthoracic echocardiography. Transthoracic echocardi-
graphy was performed for each patient to measure the left
entricular end-diastolic dimension and the distance from the
ower rim of the defects to the septal leaflet of the tricuspid
alve (DLRD-SLTV) before and after the procedure.
Statistical analysis. Data were expressed as mean  SD and
nalyzed with SPSS software version 11.0 (IBM, Ar-
onk, New York). Differences of measured data were
ompared using the Student t test and the Wilcoxon rank
um test if heterogeneity of variance existed. Differences
n categorical data were analyzed with the chi-square test.
p value  0.05 was considered statistically significant.
redictors of PPHBs were determined by a multivariate
tepwise logistic regression.
esults
Heart blocks after procedure. PPHBs occurred in 33 cases
(14.5%, 33 of 228) after the procedure (Table 1). The
average time between device placement and development of
PPHBs was 3.0  1.6 days. Among these cases, right
undle branch block (RBBB) was the most common type
19 of 33, 57.6%), followed by left bundle branch block
LBBB) 8 of 33, 24.2%) and AVB (6 of 33, 18.2%). Among
atients with procedure-induced AVB, 3 patients had
hird-degree AVB and 1 patient had second-degree Mobitz
ype 2 AVB (Table 1). The 3 cases with third-degree AVB
eveloped progressively from either a complete RBBB with
left anterior hemiblock or a complete LBBB with a
rst-degree AVB. High-degree AVB in all these 4 patients
everted to the normal sinus rhythm after administration of
ntravenous hydrocortisone and application of a temporary
Table 1. Number of Cases That Developed Heart Blocks After Closure
of pmVSD
Cases (n)
Average Time of Emergence
of PPHBs (Days)
RBBB 19 1–6
CRBBB 10 1–5
IRBBB 9 1–6
LBBB 8 1–5
CLBBB 3 1–3
ILBBB 5 2–5
AVB 6 3–7
First-degree AVB 1 3
Second-degree AVB 2 3
Mobitz type 1 1 3
Mobitz type 2 1 3
Third-degree AVB 3 4–7
Total 33
AVB  atrioventricular block; CLBBB  complete left bundle branch block; CRBBB  complete
right bundle branch block; ILBBB  incomplete left bundle branch block; IRBBB  incomplete
right bundle branch block; LBBB left bundle branch block; PPHB post-procedure heart block;pmVSD perimembranous ventricular septal defect; RBBB right bundle branch block.
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425pacemaker. Among the 33 patients suffering from PPHBs,
recovery to normal conduction before discharge occurred in
21 cases, whereas PPHBs in the remaining 12 cases (2 with
LBBB, 10 with RBBB) did not successfully recover by the
time of discharge. In addition, 26 patients had heart blocks
before the procedure (10 with RBBB, 11 with left anterior
hemiblock, and 5 with first-degree AVB). Two patients with
left anterior hemiblock before the procedure developed RBBB
afterward. The other 24 patients did not develop PPHBs.
The mean follow-up time was 56.8  14.0 months
range: 36 to 84 months). One hundred eighty-five patients
83.4%, 191 of 228) completed follow-up; 37 patients were
ost to follow-up. All the 33 patients with PPHBs com-
leted follow-up. Among the 12 patients with PPHBs at
ischarge, recovery to normal conduction occurred in 2 pa-
ients (1 with LBBB, 1 with RBBB) by the 1-month follow-up
isit, and 1 patient (RBBB) by the 3-month follow-up visit.
One patient (45 years old) was implanted with an
versized occluder (28 mm) to occlude his large VSD (18.2
m; the VSD with a ventricular septal aneurysm formation)
uring surgery. This patient was 1 of the 4 patients who
eveloped a high-degree AVB after the procedure and
ecovered to normal conduction before discharge. He de-
eloped a high-degree AVB again 42 months after the
rocedure and was implanted with a permanent pacemaker.
Risk factors of PPHB. DAVD was significantly longer (3.9
1.3 mm vs. 3.2  1.5 mm) and DLRD-SLTV (2.3  0.6
mm vs. 3.8  1.6 mm) was significantly shorter in patients
who developed PPHBs than those who did not (Table 2).
The diameter difference between the occluder and ventric-
ular septal defect (DDOV) was significantly larger in
Table 2. Risk Factors for PPHB After Procedure
Patients With
No PPHB
(n  195)
Patients With
PPHB
(n  33) p Value
Age, yrs 13.6 10.2 15.1 10.9 0.71
Weight, kg 38.8 18.9 40.2 18.8 0.38
DLRD-SLTV, mm 3.8 1.6 2.3 0.6 0.01
DAVD, mm 3.2 1.5 3.9 1.3 0.03
Diameter of pmVSD, mm 5.4 2.1 5.3 3.3 0.95
AVSDOs/SVSDOs* 91/104 15/18 0.90
SOD, mm 7.4 2.6 8.8 4.5 0.07
DDOV, mm 2.0 0.7 3.5 1.5 0.01
PASP, mm Hg 31.8 6.0 32.2 7.0 0.13
LVDD before procedure, mm 43.5 7.8 45.1 6.9 0.69
LVDD after procedure, mm 41.3 6.8 42.9 6.9 0.66
Procedure time, min 86.5 25.1 89.5 29.8 0.52
Fluoroscopy time, min 18.2 8.4 19.2 11.2 0.22
Values are mean SD or n. *Cases with AVSDOs versus cases with SVSDOs.
AVSDO  asymmetrical ventricular septal occluder; DAVD  the aortic valve to the defect;
DDOV diameter difference between the occluder and ventricular septal defect; DLRD-SLTV
the distance from lower rim of the defects to the septal leaflet of the tricuspid valve; LVDD left
ventricular end-diastolic dimension; PASP  pulmonary artery systolic pressure; PPHB  post-procedure heart block; SOD size of device; SVSDO symmetrical ventricular septal occluder.patients with PPHBs than in patients without it (3.5  1.5
mm vs. 2.0  0.7 mm, p  0.05). In the logistic regression
odel, the following parameters were independent predic-
ors of PPHBs: increasing DAVD (odds ratio [OR]: 1.88,
 0.01; 95% confidence interval [CI]: 1.14 to 3.12),
increasing DDOV (OR: 15.23, p  0.01; 95% CI: 4.97 to
46.70), and decreasing DLRD-SLTV (OR: 0.33, p  0.01;
95% CI: 0.18 to 0.59) (Table 3).
Risk factors for continuance of PPHBs after transcatheter
closure of pmVSD. PPHBs occurred earlier in those patients
whose PPHBs did not recover to normal conduction
(Table 4). In the logistic regression model, the time of
PPHB emergence was an independent predictor of PPHB
persistence (OR: 0.03, p  0.02; 95% CI: 0.00 to 0.52)
(Table 5).
Discussion
Since 2002, percutaneous techniques and devices have been
developed specifically for the closure of pmVSD. The
success rate of transcatheter closure of pmVSD has in-
creased significantly, whereas complications, such as aortic
Table 3. Odds Ratios From Multiple Logistic Models for PPHB
Predictor
Variables (mm)* Odds Ratios (95% CI) p Value
DAVD 1.88 (1.14–3.12) 0.01
DLRD-SLTV 0.32 (0.18–0.59) 0.01
DDOV 15.23 (4.97–46.70) 0.01
*Other variables tested but not reaching statistical significance were age, weight, DLRD-SLTV,
diameter of pmVSD, SOD, PASP, LVDD before procedure, LVDD after procedure, procedure time.
CI confidence interval; other abbreviations as in Tables 1 and 2.
Table 4. Risk Factors for PPHB Persistence After the Procedure
PPHB RNC
(n  24)
PPHB NRNC
(n  9) p Value
Age, yrs 15.8 11.8 13.6 9.1 0.89
Weight, kg 41.6 20.8 37.3 14.7 0.93
DAVD, mm 3.8 1.4 3.9 1.2 0.99
DLRD-SLTV, mm 2.2 0.5 2.5 0.8 0.47
Diameter of pmVSD, mm 6.6 3.4 5.1 1.2 0.38
SOD, mm 9.7 5.0 7.6 1.9 0.43
DDOV, mm 3.1 1.8 2.5 0.8 1.00
PASP, mm Hg 33.9 6.3 28.6 7.3 0.14
LVDD before procedure, mm 46.0 7.8 43.4 4.2 0.59
LVDD after procedure, mm 43.2 7.9 42.2 4.2 0.86
Time of HB emergence after
procedure, days
3.6 1.5 1.6 0.8 0.01
Procedure time, min 90.6 33.2 87.2 22.9 0.99
Fluoroscopy time, min 21.1 12.8 15.6 6.2 0.93
Values are mean SD.
HB  heart block; NRNC  no recovery to normal conduction; RNC  recovery to normalconduction; other abbreviations as in Table 2.
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426or tricuspid regurgitation and device motion, decreased
significantly (4–7,13,17–19). However, the incidence of
heart blocks after closure of pmVSD has remained high,
with complete AVB being the worst type (2,8–16). As a
result, this method has not been widely accepted.
In this study, 14.5% of patients developed PPHBs.
Among them, RBBB was the most common type of PPHB
(57.6%), followed by LBBB and AVB. RBBB may be the
most common type because the right bundle branch is
spindly and easily damaged. However, most PPHBs re-
verted to normal conduction. High-degree AVB is the most
serious PPHB. Four patients developed high-degree AVB
(1.8%) in our study; its incidence has ranged from 1.1% to
5.7% in other reports (2,5–7,13,14,17). In addition, other
types of PPHBs, including RBBB, LBBB, and first-degree
AVB, could progress to high-degree AVB (9,10,17,20).
Most PPHBs, including high-degree AVB, were tran-
sient after closure of pmVSD and could recover to normal
conduction spontaneously or by treatment with intravenous
hydrocortisone and a temporary pacemaker (8–10,17,21).
In practice, PPHBs occurred most frequently 2 to 7 days
after device closure of pmVSD (4,6,7,9,10,15–18), but
sometimes may also occur 2 to 4 weeks or even later (i.e., 12
to 36 months later) (4–6,9–11,14–16). As a result, patients
should be closely observed for at least 7 days in the hospital
and during follow-up visits.
In this study, a shorter DLRD-SLTV (OR: 0.33) or
longer DAVD (OR: 1.88) were identified as risk factors for
PPHBs. Our study showed that the likelihood of PPHBs
increased the closer the VSD was to the tricuspid valve,
or the farther it was from the aortic valve. This may be
related to the conduction system crossing through the
nearby tricuspid valve. If the location of the VSD is close to
the tricuspid valve, the device may disturb atrioventricular
conduction by direct traumatic compression. Furthermore,
the device may give rise to an inflammatory reaction or scar
formation in the conduction tissue. An oversized device
(OR: 15.23) was another risk factor associated with the
occurrence of PPHBs in our study, as has also been reported
elsewhere (6,7).
Our study showed that the earlier a PPHB developed
Table 5. Odds Ratios From Multiple Logistic Models for Continuance
of PPHBs
Predictor Variables* Odds Ratios (95% CI) p Value
PASP, mm Hg 0.23 (0.05–1.15) 0.07
SOD, mm 0.18 (0.03–1.32) 0.09
HB emergence after procedure, days 0.03 (0.00–0.52) 0.02
*Other variables tested but not reaching statistic significance were age, weight, DAVD, DLRD-
SLTV, diameter of pmVSD, DDOV (diameter difference between the occluder and ventricular
septal defect), LVDD before procedure, LVDD after procedure, procedure time.
CI confidence interval; other abbreviations as in Tables 2, 3, and 4.after closure of the pmVSD, the more difficult was arecovery to normal conduction. It is notable that for patients
whose PPHBs did not recover to normal, it may have been
due to the immediate effect of compression of the conduc-
tion system by the VSD occluder (22).
Conclusions
The incidence of PPHBs after transcatheter closure of
pmVSD is relatively high, but the outcome of PPHBs after
transcatheter closure of pmVSD was satisfactory, as most
patients recovered to normal conduction. More careful
monitoring after transcatheter closure of pmVSD should be
applied for patients whose pmVSD is close to the tricuspid
valve and far away from the aortic valve. Oversized devices
should be avoided.
Reprint requests and correspondence: Dr. Rong Yang, Depart-
ment of Cardiology, First Affiliated Hospital of Nanjing Medical
University, 300 Guangzhou Road, Nanjing 210029, China.
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